Yayınlar & Eserler

Yayın Ağı
Makaleler 39
Tümü (39)
SCI-E, SSCI, AHCI (39)
SCI-E, SSCI, AHCI, ESCI (39)
Scopus (39)
TRDizin (3)

1. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Guzel H. G., et al.
JOURNAL OF CHEMOTHERAPY , 2024 (SCI-Expanded, Scopus) identifier identifier identifier

2. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)

YAŞAR H. A., AKTAŞ B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., et al.
Clinical Genitourinary Cancer , cilt.22, sa.3, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

3. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Machiels J., Tao Y., Licitra L., Burtness B., Tahara M., Rischin D., et al.
The Lancet Oncology , 2024 (SCI-Expanded, Scopus) identifier identifier identifier identifier

4. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study

Guven D. C., Aykan M. B., MUĞLU H., BAYRAM E., Helvaci K., DURSUN B., et al.
Cancer Medicine , cilt.13, sa.1, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

5. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

Yildirim M. E., Karadurmuş N., Ökten İ. N., TÜRK H. M., Urakçı Z., Arslan Ç., et al.
Journal of Oncology Pharmacy Practice , 2024 (SCI-Expanded, Scopus) identifier identifier identifier

6. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

AKYILDIZ A., GÜVEN D. C., Ozluk A. A., Ismayilov R., Mutlu E., Unal O. U., et al.
Medicine , cilt.102, sa.45, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

7. Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium

Erol C., Yekedüz E., Tural D., Karakaya S., Şentürk Öztaş N., Uçar G., et al.
Urologia Internationalis , cilt.107, sa.6, ss.595-601, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

8. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

Yekedüz E., Karakaya S., Ertürk İ., Tural D., Uçar G., Şentürk Öztaş N., et al.
Clinical Genitourinary Cancer , cilt.21, sa.1, ss.175-182, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

9. Surgical, pathological and clinical features of advanced collorectal cancers with metastasectomy. "Onco-Colon Turkey Registry" real-life data

Karadurmus N., Yildirim E., Yalcin S., Gumus M., Bilir C., Cubukcu E., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.4, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

10. Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice.

Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Erman M., Urun Y., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.6, 2022 (SCI-Expanded, Scopus) identifier

11. Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer.

Kefeli U., Arslan C., Yildirim M. E., Isikdogan A., Karadurmus N., Karabulut B., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

12. Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.

Disel U., Kose F., Bilici A., Ozguroglu M., Saglam S., Seker M., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15, 2020 (SCI-Expanded, Scopus) identifier

13. Prognostic role of inflammatory biomarkers in metastatic breast cancer

Petekkaya I., Unlu O., Roach E. C., Gecmez G., Okoh A. K., BABACAN T., et al.
JOURNAL OF BUON , cilt.22, sa.3, ss.614-622, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

14. Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update

Arslan C., Dizdar O., ALTUNDAG K.
EXPERT OPINION ON PHARMACOTHERAPY , cilt.15, sa.12, ss.1643-1658, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

15. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy

OZCAN M. F., Dizdar O., DINCER N., BALCI S., Guler G., GOK B., et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS , cilt.31, sa.8, ss.1709-1715, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

16. Association of breast cancer subtypes and body mass index

Petekkaya I., ŞAHİN U., Gezgen G., Solak M., YÜCE D., DİZDAR Ö., et al.
TUMORI J , cilt.99, sa.2, ss.129-133, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

17. Does Androgen Receptor Have a Prognostic Role in Patients with Estrogen/Progesterone-Negative and c-erbB-2-Positive Breast Cancer?

Arslan C., Isik M., GÜLER G., Kulac I., Solak M., Turker B., et al.
AMERICAN SURGEON , cilt.78, sa.9, ss.992-999, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

18. Frequency of HCV infection in renal cell carcinoma patients

Budakoglu B., Aksoy S., ARSLAN Ç., Uyeturk U., Babacan N. A., Ozcan M. F., et al.
MEDICAL ONCOLOGY , cilt.29, sa.3, ss.1892-1895, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

19. Increased mean corpuscular volume of erythrocytes predicts the response to metronomic cyclophosphamide, capecitabine and bevacizumab treatment: Is it true for capecitabine treatment or more?

Arslan C., Altundag K.
BREAST , cilt.21, sa.4, ss.612-613, 2012 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

20. Pituitary Gland Metastasis of Breast Cancer: A Case Report

Ozkan C., ARSLAN Ç., KILIÇ M., ERMAN M., Altundag K.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.22, sa.1, ss.42-45, 2012 (SCI-Expanded, Scopus, TRDizin) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

21. Screening Colonoscopy Participation in Turkish Colorectal Cancer Patients and their First Degree Relatives

KILIÇKAP S., ARSLAN Ç., Rama D., YALÇIN Ş.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.13, sa.6, ss.2829-2832, 2012 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

22. Emerging drugs in metastatic breast cancer: an update

Arslan C., Altundag K., Dizdar O.
EXPERT OPINION ON EMERGING DRUGS , cilt.16, sa.4, ss.647-667, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

23. Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer

BULUT N., AKSOY S., DİZDAR Ö., Dede D. S., Arslan C., DOĞAN E., et al.
MEDICAL ONCOLOGY , cilt.28, 2011 (SCI-Expanded, Scopus) identifier identifier identifier

24. Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response

ARSLAN Ç., AKSOY S., DİZDAR Ö., KURT M., Guler N., Ozisik Y., et al.
TUMORI , cilt.97, sa.6, ss.711-716, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

25. Acute promyelocytic leukemia in a young patient with breast cancer

KARA O., Ozdemir E., Arslan C., DOGAN E., ALTUNDAG K.
MEDICAL ONCOLOGY , cilt.28, sa.1, ss.249-250, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

26. Zoledronic acid and atrial fibrillation in cancer patients

ARSLAN Ç., AKSOY S., DİZDAR Ö., Dede D. S., HARPUTLUOĞLU H., ALTUNDAĞ M. K.
SUPPORTIVE CARE IN CANCER , cilt.19, sa.3, ss.425-430, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

27. Gastric cancer after cadaveric liver transplantation in a patient with autoimmune hepatitis: A case report and review of the literature

ARSLAN Ç., KILIÇKAP S., YALÇIN Ş.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.22, sa.1, ss.73-76, 2011 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma identifier identifier identifier

28. FREQUENCY OF CANCER TYPES IN PATIENTS AGED 65 AND OLDER: RESULTS FROM CANCER REGISTRY DATABASE OF HACETTEPE UNIVERSITY HOSPITALS

Arslan C., KILIÇKAP S., Dede D. S., HAYRAN K. M., ERMAN M., ÇELİK İ., et al.
TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI , cilt.14, sa.3, ss.187-192, 2011 (SCI-Expanded, SSCI, Scopus, TRDizin) Sürdürülebilir Kalkınma identifier identifier

29. Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature

Arslan C., Sari E., Aksoy S., Altundag K.
EXPERT OPINION ON THERAPEUTIC TARGETS , cilt.15, sa.1, ss.21-30, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

30. Other malignancies in patients with breast cancer: a single institute experience

Dogan E., AKSOY S., DİZDAR Ö., ŞENER DEDE D., ARSLAN Ç., Ozisik Y., et al.
MEDICAL ONCOLOGY , cilt.27, sa.4, ss.1434-1435, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

31. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma

Dogan E., AKSOY S., ARSLAN Ç., ŞENER DEDE D., Altundag K.
MEDICAL ONCOLOGY , cilt.27, sa.4, ss.1436-1437, 2010 (SCI-Expanded, Scopus) identifier identifier identifier

32. Serum levels of CEA and CA 15-3 in triple-negative breast cancer at the time of diagnosis

ŞENER DEDE D., ARSLAN Ç., Altundag K.
MEDICAL ONCOLOGY , cilt.27, sa.4, ss.1429, 2010 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

33. The role of zoledronic acid in the adjuvant treatment of breast cancer: current perpectives

Tonyali O., ARSLAN Ç., Altundag K.
EXPERT OPINION ON PHARMACOTHERAPY , cilt.11, sa.16, ss.2715-2725, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

34. The Effect on Prognosis of Postoperative CA 19-9 Level in Patients With Pancreatic Cancer

KILIÇKAP S., ARSLAN Ç.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.33, sa.3, ss.320, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

35. Systemic treatment in breast-cancer patients with brain metastasis

Arslan C., DİZDAR Ö., Altundag K.
EXPERT OPINION ON PHARMACOTHERAPY , cilt.11, sa.7, ss.1089-1100, 2010 (SCI-Expanded, Scopus) identifier identifier identifier

36. Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma

KILIÇKAP S., ARSLAN Ç., ŞENEL S., ATASEVEN H.
JOURNAL OF CLINICAL ONCOLOGY , cilt.28, sa.6, 2010 (SCI-Expanded, Scopus) identifier identifier identifier

37. Estrogen receptor immunohistochemistry cutoff value: Standardization is needed

ARSLAN Ç., DİZDAR Ö., Altundag K.
HUMAN PATHOLOGY , cilt.41, sa.1, ss.150, 2010 (SCI-Expanded, Scopus) identifier identifier identifier

38. Pharmacotherapy of triple-negative breast cancer

ARSLAN Ç., DİZDAR Ö., Altundag K.
EXPERT OPINION ON PHARMACOTHERAPY , cilt.10, sa.13, ss.2081-2093, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

39. Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients

KILIÇKAP S., ARSLAN Ç.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION , cilt.301, sa.14, ss.1435, 2009 (SCI-Expanded, Scopus) identifier identifier identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 5

1. Early stage "T2N0" breast cancer: Does it consist two different "T2" stages?

Arslan C., Sahin U., Kizilarslanoglu C., Solak M., Gullu I. H., Ozisik Y., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

2. Clinicopathologic characteristics of pure papillary breast carcinoma

Turkoz F. P., Solak M., Keskin O., Arik Z., Arslan C., Kertmen N., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) identifier

3. Inflammatory markers in metastatic breast cancer.

Sahin U., Petekkaya H., Gecmez G., Babacan T., Roach E. C., Sarici S. F., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

4. Impact of obesity in postmenopausal early breast cancer patients receiving frontline adjuvant aromatase inhibitors.

Sahin U., Petekkaya I., Arslan C., Sarici S. F., Solak M., Keskin O., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

5. Retrospective analysis of octagenarian breast cancer patients: Multicenter retrospective study.

Dizdar O., Arslan C., Eren T., Yalcin S., Kucukoztas N., Aksoy S., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma identifier
Metrikler

Yayın

44

Yayın (WoS)

44

Yayın (Scopus)

39

Atıf (WoS)

235

H-İndeks (WoS)

9

Atıf (Scopus)

211

H-İndeks (Scopus)

8

Açık Erişim

4
BM Sürdürülebilir Kalkınma Amaçları